Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Embolism × apixaban × Clear all

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 17 Neoplasms 12 Venous Thrombosis 8 Pulmonary Embolism 7 Thrombosis 4 Multiple Myeloma 3 Upper Extremity Deep Vein Thrombosis 2 Neoplasm Metastasis 2 Myeloproliferative Disorders 2 Intracranial Thrombosis 2 Thromboprophylaxis 1 Thromboembolism 1 Thrombocytopenia 1 Thrombocythemia, Essential 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Pancreatic Neoplasms 1 Neoplasms, Plasma Cell 1 Mesenteric Ischemia 1 Lymphoma 1 Hematologic Neoplasms 1 Fibrosis 1 Embolism 1 Catheter-Related Infections 1 Carcinoma, Hepatocellular 1

Interventions

edoxaban 1 apixaban 1 Warfarin 1 Rivaroxaban 1 Heparin, Low-Molecular-Weight 1 Dalteparin 1 Dabigatran 1 4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04618913 2026-03-12

VICTORIE

Pfizer

Active not recruiting

Classical hematology

Embolism, Neoplasms, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡